个人中心| | 帮助
高级检索
当前位置： 首页 > 详情页

Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.

| 认领 | 导出 | |

文献详情

资源类型：
WOS体系：
Pubmed体系：

收录情况： ◇ ESCI

作者：
Yang Xue-Ning[1] ; Yan Hong-Hong[1] ; Wang Jun[2] ; Chu Xiang-Yang[3] ; Liu Zhi-Dong[4] ; Shen Yi[5] ; Ma Hai-Tao[6] ; Fu Xiang-Ning[7] ; Hu Jian[8] ; Zhou Nai-Kang[9] ; Liu Yong-Yu[10] ; Zhou Xin-Ming[11] ; Li Jing-Song[12] ; Yang Kang[13] ; Li Jian[14] ; Xu Lin[15] ; Wang Si-Yu[16] ; Wang Qun[17] ; Liu Lun-Xu[18] ; Xu Shun[19] ; Chen Zhong-Yuan[20] ; Lou Hong-He[21] ; Wang Chang-Li[22] ; Cheng Ying[23] ; Liu Si-Yang[1] ; Zhang Xu-Chao[1] ; Zhong Wen-Zhao[1] ; Wu Yi-Long[1,*1] ;
机构： [1]Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital &Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. [2]Thoracic Surgery Department, Peking University People's Hospital, Beijing, People's Republic of China. [3]Thoracic Surgery Department, 301 Hospital, Beijing, People's Republic of China. [4]Thoracic Surgery Department II, Beijing Chest Hospital, Capital Medical University, Beijing, People's Republic of China. [5]Thoracic Surgery Department, the Affiliated Hospital of Medical College, Qingdao University, Qingdao, People's Republic of China. [6]Thoracic Surgery Department, the First Affiliated Hospital of Soochow University, Suzhou, People's Republic of China. [7]Thoracic Surgery Department, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. [8]Thoracic Surgery Department, The First Affiliated Hospital of Medical School of Zhejiang University, Hangzhou, People's Republic of China. [9]Thoracic Surgery Department, 309 Hospital, Beijing, People's Republic of China. [10]Thoracic Surgery Department, Liaoning Cancer Hospital & Institute, Shenyang, People's Republic of China. [11]Thoracic Surgery Department, Zhejiang Cancer Hospital, Hangzhou, People's Republic of China. [12]Thoracic Surgery Department, Union Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, People's Republic of China. [13]Thoracic Surgery Department, The First Affiliated Hospital of Third Military Medical University, Chongqing, People's Republic of China. [14]Thoracic Surgery Department, Peking University First Hospital, Beijing, People's Republic of China. [15]Thoracic Surgery Department, Jiangsu Cancer Hospital, Nanjing, People's Republic of China. [16]Thoracic Surgery Department, Sun Yat-Sen University Cancer Center, Guangzhou, People's Republic of China. [17]Thoracic Surgery Department, Zhongshan Hospital Fudan University, Shanghai, People's Republic of China. [18]Thoracic Surgery Department, West China Hospital, Sichuan University, Chengdu, People's Republic of China. [19]Thoracic Surgery Department, The First Hospital of China Medical University, Shenyang, People's Republic of China. [20]Thoracic Surgery Department, Ruijin Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, People's Republic of China. [21]Thoracic Surgery Department, The First Affiliated Hospital, Sun Yat-Sen University, Guangzhou, People's Republic of China. [22]Lung Cancer Center, Tianjin Medical University Cancer Institute & Hospital, Tianjin, People's Republic of China. [23]Medical Oncology, Jilin Cancer Hospital, Changchun, People's Republic of China.
出处：
DOI： 10.1016/j.jtocrr.2021.100257

摘要：
The adjuvant treatment of patients with resected lung adenocarcinoma (LUAD) remains unstandardized. We analyzed the survival outcomes of these patients based on EGFR mutation status and adjuvant chemotherapy treatment.This noninterventional real-world study (ICAN) enrolled Chinese patients with resected stages I to III LUAD from April 8, 2010, to December 31, 2010. Tumor EGFR mutation status and 3-year disease-free survival (DFS) were determined. The extension phase provided long-term follow-up with overall survival (OS) as the primary end point. Secondary end points included DFS and prognostic factors of survival. Survival outcomes based on adjuvant chemotherapy treatment, EGFR mutation status, and postoperative stage were analyzed post hoc.Among 568 patients in the ICAN cohort, 472 continued to the extension phase and remained eligible. The 3-year DFS rate was 58.8%. In the extension cohort, 260 patients (55.1%) had EGFR-mutant disease and 207 (43.9%) received adjuvant chemotherapy. At a median follow-up of 109.0 (95% confidence interval [CI]: 106.6-111.4) months, median OS and DFS were 103.3 (95% CI: 101.7-104.9) and 67.4 (95% CI: 49.7-85.2) months, respectively. The 5-year OS and DFS rates were 68.9% (95% CI: 64.3-73.6) and 52.9% (95% CI: 48.2-57.7), respectively. EGFR wild-type disease was a significant independent predictor of worse OS (HR = 1.24, 95% CI: 1.07-1.44, p= 0.004) based on the Cox regression analysis of common factors. Post hoc subgroup analysis revealed that survival outcomes were not significantly different with adjuvant chemotherapy regardless of EGFR mutation status across all postoperative stages.EGFR mutations are common in operable LUAD, and recurrence and mortality after resection were considerable. Adjuvant chemotherapy did not improve survival outcomes, regardless of EGFR mutation status and postoperative stage.© 2021 The Authors.

基金：
This study was funded by AstraZeneca and the Chinese Thoracic Oncology Group (study number: CTONG1802). Medical writing support, funded by AstraZeneca, was provided by Qing Yun Chong, Alice Carruthers, Tim Stentiford, Henry Chung, and Rachael Profit (Nucleus Global, Shanghai, People’s Republic of China) in accordance with the Good Publication Practice 3 guidelines.
语种：
外文
被引次数：
WOS：
PubmedID：
JCR分区：
出版当年[2022]版：
无
最新[2023]版：
Q2 ONCOLOGY Q2 RESPIRATORY SYSTEM

影响因子： 最新[2023版] 最新五年平均 出版当年[2021版] 出版当年五年平均 出版前一年[2021版] 出版后一年[2023版]

第一作者：
第一作者机构： [1]Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital &Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China.
共同第一作者：
通讯作者：
通讯机构： [1]Guangdong Lung Cancer Institute, Guangdong Provincial People's Hospital &Guangdong Academy of Medical Sciences, Guangzhou, People's Republic of China. [*1]Guangdong Lung Cancer Institute, Guangdong Provincial People’s Hospital & Guangdong Academy of Medical Sciences, Yuexiu District, Guangzhou 510080, People’s Republic of China.
推荐引用方式(GB/T 7714)：
Yang Xue-Ning,Yan Hong-Hong,Wang Jun,et al.Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.[J].JTO CLINICAL AND RESEARCH REPORTS.2022,3(1):doi:10.1016/j.jtocrr.2021.100257.
APA：
Yang Xue-Ning,Yan Hong-Hong,Wang Jun,Chu Xiang-Yang,Liu Zhi-Dong...&Wu Yi-Long.(2022).Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study..JTO CLINICAL AND RESEARCH REPORTS,3,(1)
MLA：
Yang Xue-Ning,et al."Real-World Survival Outcomes Based on EGFR Mutation Status in Chinese Patients With Lung Adenocarcinoma After Complete Resection: Results From the ICAN Study.".JTO CLINICAL AND RESEARCH REPORTS 3..1(2022)

资源点击量：43377 今日访问量：0 总访问量：3120 更新日期：2024-09-01 建议使用谷歌、火狐浏览器 常见问题

版权所有©2020 四川省肿瘤医院 技术支持：重庆聚合科技有限公司 地址：成都市人民南路四段55号